Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $89.11 Average PT from Brokerages

Keros Therapeutics, Inc. (NASDAQ:KROS) has been assigned an average recommendation of “Buy” from the eleven brokerages that are presently covering the company, Marketbeat reports. Eleven equities research analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $89.11.

Several equities research analysts have weighed in on the company. Cantor Fitzgerald began coverage on Keros Therapeutics in a report on Thursday, October 24th. They issued an “overweight” rating for the company. Scotiabank assumed coverage on shares of Keros Therapeutics in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 price target on the stock. Bank of America decreased their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Finally, Guggenheim assumed coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They set a “buy” rating and a $96.00 target price on the stock.

Keros Therapeutics Stock Performance

Shares of Keros Therapeutics stock opened at $59.94 on Tuesday. Keros Therapeutics has a 52-week low of $27.31 and a 52-week high of $73.00. The company’s 50 day moving average price is $56.24 and its 200-day moving average price is $51.91. The stock has a market capitalization of $2.25 billion, a price-to-earnings ratio of -11.68 and a beta of 1.23.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). The firm had revenue of $0.04 million during the quarter. Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. During the same quarter last year, the firm earned ($1.27) EPS. As a group, equities research analysts forecast that Keros Therapeutics will post -4.9 earnings per share for the current fiscal year.

Insider Activity at Keros Therapeutics

In other Keros Therapeutics news, Director Carl L. Gordon sold 250,000 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total value of $11,002,500.00. Following the sale, the director now owns 119,522 shares in the company, valued at approximately $5,260,163.22. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 22.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Keros Therapeutics

Several hedge funds have recently added to or reduced their stakes in KROS. Mirae Asset Global Investments Co. Ltd. grew its position in Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after purchasing an additional 280 shares during the last quarter. Values First Advisors Inc. bought a new stake in shares of Keros Therapeutics during the third quarter valued at approximately $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Keros Therapeutics in the 2nd quarter worth approximately $128,000. Ameritas Investment Partners Inc. lifted its position in Keros Therapeutics by 14.5% in the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after acquiring an additional 324 shares in the last quarter. Finally, Quest Partners LLC boosted its stake in Keros Therapeutics by 23,945.0% during the 2nd quarter. Quest Partners LLC now owns 4,809 shares of the company’s stock valued at $220,000 after purchasing an additional 4,789 shares during the last quarter. 71.56% of the stock is owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.